{"id":"https://openalex.org/W4390128641","doi":"https://doi.org/10.1016/j.jval.2023.09.1708","title":"HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis","display_name":"HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis","publication_year":2023,"publication_date":"2023-12-01","ids":{"openalex":"https://openalex.org/W4390128641","doi":"https://doi.org/10.1016/j.jval.2023.09.1708"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2023.09.1708","doi":"https://doi.org/10.1016/j.jval.2023.09.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.09.1708","pdf_url":"https://www.valueinhealthjournal.com/article/S1098-3015(23)04838-6/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.valueinhealthjournal.com/article/S1098-3015(23)04838-6/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066803723","display_name":"A. Mumford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Mumford","raw_affiliation_strings":["Initiate Consultancy, Northampton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Initiate Consultancy, Northampton, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092132395","display_name":"O. Darlington","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"O. Darlington","raw_affiliation_strings":["Initiate Consultancy, NA, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Initiate Consultancy, NA, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016945599","display_name":"S.J. Lyttle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S.J. Lyttle","raw_affiliation_strings":["Initiate Consultancy, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Initiate Consultancy, London, UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007952516","display_name":"Anne L. Shaw","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Shaw","raw_affiliation_strings":["Initiate Consultancy, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Initiate Consultancy, London, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3200,"currency":"USD","value_usd":3200},"apc_paid":{"value":3200,"currency":"USD","value_usd":3200},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"12","first_page":"S324","last_page":"S324"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5005000233650208,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.5005000233650208,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.4867999851703644,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T14396","display_name":"Healthcare Regulation","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rare-diseases","display_name":"rare diseases","score":0.8640000224113464},{"id":"https://openalex.org/keywords/pharmaceutical-benefits-advisory-committee","display_name":"Pharmaceutical Benefits Advisory Committee","score":0.9869999885559082},{"id":"https://openalex.org/keywords/drug-reimbursement","display_name":"drug reimbursement","score":0.6050000190734863},{"id":"https://openalex.org/keywords/cost-effectiveness-analysis","display_name":"cost-effectiveness analysis","score":0.7279999852180481},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.4189999997615814},{"id":"https://openalex.org/keywords/australia","display_name":"Australia","score":0.49799999594688416}],"concepts":[{"id":"https://openalex.org/C3017489713","wikidata":"https://www.wikidata.org/wiki/Q4686866","display_name":"Advisory committee","level":2,"score":0.8118370771408081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33819901943206787},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.32376813888549805},{"id":"https://openalex.org/C3116431","wikidata":"https://www.wikidata.org/wiki/Q31728","display_name":"Public administration","level":1,"score":0.1717992126941681}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2023.09.1708","doi":"https://doi.org/10.1016/j.jval.2023.09.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.09.1708","pdf_url":"https://www.valueinhealthjournal.com/article/S1098-3015(23)04838-6/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2023.09.1708","doi":"https://doi.org/10.1016/j.jval.2023.09.1708","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.09.1708","pdf_url":"https://www.valueinhealthjournal.com/article/S1098-3015(23)04838-6/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4390128641.pdf","grobid_xml":"https://content.openalex.org/works/W4390128641.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4415730258","https://openalex.org/W2061556311","https://openalex.org/W2118526515","https://openalex.org/W3185268925","https://openalex.org/W2070554741","https://openalex.org/W2324317592","https://openalex.org/W2557309514","https://openalex.org/W6908214299","https://openalex.org/W3033478530","https://openalex.org/W4240585945"],"abstract_inverted_index":{"The":[0,32],"Pharmaceutical":[1],"Benefits":[2],"Advisory":[3],"Committee":[4],"(PBAC)":[5],"plays":[6],"a":[7],"crucial":[8],"role":[9],"in":[10,20,48],"evaluating":[11],"the":[12,23,42,53,60],"clinical":[13],"and":[14,40,57],"cost-effectiveness":[15],"of":[16,34,59],"medications":[17],"for":[18,25,44],"reimbursement":[19],"Australia.":[21],"However,":[22],"process":[24],"rare":[26,49],"diseases":[27],"can":[28],"pose":[29],"unique":[30],"challenges.":[31],"objective":[33],"this":[35],"study":[36],"was":[37],"to":[38],"identify":[39],"analyse":[41],"reasons":[43],"negative":[45],"PBAC":[46],"reviews":[47],"diseases,":[50],"focusing":[51],"on":[52],"objectives,":[54],"methods,":[55],"results,":[56],"conclusions":[58],"assessment":[61],"process.":[62]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-12-23T00:00:00"}